FRC
FRC Logo
Sign InGet Access

Connect With Us

Stay updated with our latest research and insights

Fundamental Research Corp Logo

Highly ranked equity research firm providing institutional grade tools and analysis to all investors worldwide. Trusted by global investors for over 20+ years.

20+ Years

Policies

  • Privacy Policy
  • Terms of Service
  • Disclaimer

Company

  • About Us
  • Our Team
  • Contact Us

Resources

  • Videos
  • Research Reports
  • FAQ

© 2026 Fundamental Research Corp. All Rights Reserved.

Professional investment research since 2003

Home
Research
Get Access
Sign In
Shield Therapeutics plc Stock AnalysisComprehensive stock analysis for Shield Therapeutics plc (SHIEF) including live price, Snowflake performance metrics, financial statements, and investment research.Stock AnalysisSHIEF
SHIEF
Shield Therapeutics plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SHIEF
Home🔹Stocks🔹Shield Therapeutics plc

Shield Therapeutics plc

SHIEF•OTC

Shield Therapeutics plc

SHIEF•OTC
Market cap
$150.91M
Sentiment

Your view on SHIEF

Mkt Cap
$150.91M
Sentiment
Your view
SHIEF
Shield Therapeutics plc
  • Company Overview
  • FRC Research
  • Financial Data
  • Peer Comparison
  • Ownership & News
SHIEF
Company Overview

Overview

What the company does, where it operates, and who runs it.

About Shield Therapeutics plc

Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Anders Lundstrom
Headquarters
Northern Design Centre, Gateshead, GB
Industry
Drug Manufacturers - Specialty & Generic
Sector
Healthcare
CEO
Anders Lundstrom
Headquarters
Northern Design Centre, Gateshead, GB
Description

Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.

Infographics

Visual summary of the business at a glance.

FRC Research

Media

Videos and interviews covering the company.

Financial Data

Stock Data

Price chart, volume, and trading data.

Fair Value

What FRC thinks the stock is worth vs. the current price.

Financial Ratios

Profitability, returns, valuation, and leverage ratios.

Dividend Analysis

Yield, payout ratio, and dividend coverage metrics.

Earnings Analysis

EPS history, beat rate, and upcoming earnings reports.

Financial Statements

Income statement, balance sheet, and cash flow statements.

Peer Comparison

Comparables

List of peer companies in the same industry.

Ownership & News

Institutional Ownership

Which funds and firms own the stock.

Insider Trading

Recent buying and selling by company executives.

Senate Trading

U.S. Senator disclosures filed under the STOCK Act.

News

Latest headlines and market coverage.

News

Latest Market News